TriSalus Life Sciences, Inc.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
December 31, 2024 and 2023
(in thousands, except share and per share data)
| 2024 | 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $8,525 | 11,777 |
| Accounts receivable, net | 5,087 | 3,554 |
| Inventory | 4,048 | 2,545 |
| Prepaid expenses | 3,009 | 2,986 |
| Total current assets | 20,669 | 20,862 |
| Property and equipment, net | 1,669 | 2,091 |
| Right-of-use assets | 1,210 | 1,179 |
| Other assets | 423 | 466 |
| Total assets | $23,971 | $24,598 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Trade payables | $2,274 | $3,391 |
| Accrued liabilities | 7,355 | 10,556 |
| Short-term lease liabilities | 216 | 351 |
| Other current liabilities | 383 | 389 |
| Total current liabilities | 10,228 | 14,687 |
| Long-term debt, net of unamortized discount and debt issuance costs | 22,084 | — |
| Revenue base redemption liability | 507 | — |
| Long-term lease liabilities | 1,329 | 1,244 |
| Contingent earnout liability | 7,401 | 18,632 |
| Warrant and SEPA liabilities | 8,316 | 17,100 |
| Total liabilities | 49,865 | 51,663 |
| Commitments and contingencies | ||
| Stockholders’ deficit: | ||
| Preferred Stock, Convertible Series A, $0.0001 par value per share, $10.00 liquidation value per share. Authorized 10,000,000 shares at December 31, 2024 and 2023, respectively; issued and outstanding, 3,985,002 and 4,015,002 shares at December 31, 2024 and 2023, respectively | — | — |
| Common stock, $0.0001 par value per share. Authorized 400,000,000 shares at December 31, 2024 and 2023, respectively; issued and outstanding 31,279,264 shares and 26,413,213 shares at December 31, 2024 and 2023, respectively | 3 | 2 |
| Additional paid-in capital | 253,652 | 222,437 |
| Accumulated deficit | (279,549) | (249,504) |
| Total stockholders’ deficit | (25,894) | (27,065) |
| Total liabilities and stockholders’ deficit | $23,971 | $24,598 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.